Many potential announcements to come, lopes.Sales are lumpy....

Many potential announcements to come, lopes.

Sales are lumpy. Heaven forbid if the lump goes our way, we may get a positive monthly sales update that would ease the fears of those that sales have taken a massive hit from covid (they still may have, though, time will tell).

We are expecting announcements of partnerships with major medical groups, in 1Q CY2021 ( which I would consider short term, personally).

We are making inroads with military contracts, having just signed another base. Announcements regarding this could drop any time.

We are also making first sales in a number of other countries, so there is the potential for areas of growth announcements as well as partnership announcements.

I guess we aren't really depending on results of some long shot trials, like other aussie biotechs. Or the results of battling with the FDA, as the FDA seems to like our legitimate products.

And I'm not too worried about minor share sales from directors. I'm confident in our board. They're able to design trials that lead to approval, after all.

If that's your cup of tea there's another place to look Although the market cap over there doesn't seem to factor in the fact they don't have an approved product to sell....